RxDoctor Payments Data

Tyler Buchanan

Family · Clovis, NMNPI 1962985606

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,497 and has fallen 99.3% since, to $18 in 2025. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,298in general payments, 2019–2025

Across 431 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$911
  • UCB, Inc.$547
  • Neurocrine Biosciences, Inc.$472
  • Supernus Pharmaceuticals, Inc.$463
  • SK Life Science, Inc.$419
  • Lilly USA, LLC$285
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,298 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$26,514
Medicare patients
173
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate32$70,515
Oxcarbazepine35$4,988
PaxlovidNirmatrelvir/Ritonavir15$4,287
Divalproex Sodium34$4,267
Levetiracetam65$3,250
Carbamazepine20$2,005
Divalproex Sodium ErDivalproex Sodium13$1,204
Topiramate23$1,093
Lamotrigine39$940
Phenytoin Sodium Extended17$604
Zonisamide13$438
Gabapentin13$387
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav47$345
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$206
Cefdinir12$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$39$70,51532 claims
PfizerPaxlovid$48$4,28715 claims
Upsher-smith Laboratories LLCTopiramate$15$1,09323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.

Other family in Clovis

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →